Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Janssen-Cilag Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (144)
Cancellation by sponsor (46)
Australian public assessment report (AusPar) (37)
Prescription medicine registration (29)
Designation or determination (6)
Prescription medicine decision summary (5)
Prescription medicine evaluation (3)

Date

2026 (5)
2025 (24)
2024 (16)
2023 (16)
2022 (11)
2021 (15)
2020 (25)
2019 (7)
2018 (9)
2017 (19)
2016 (19)
2015 (7)
2014 (12)
2013 (5)
2012 (5)
2011 (4)
2010 (19)
2009 (6)
2008 (2)
2007 (5)
2006 (3)
2005 (5)
2003 (6)
2002 (2)
2000 (9)
1998 (9)
1996 (1)
1994 (1)
1993 (3)

Search

Sponsor content

270 result(s) found, displaying 101 to 110

PREZISTA darunavir 300mg tablets bottle Cancelled under Section 30(1)(c) of the Act

4 November 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
PREZISTA darunavir 150mg tablets bottle Cancelled under Section 30(1)(c) of the Act

4 November 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
IMBRUVICA (Janssen-Cilag Pty Ltd)

16 October 2020

Prescription medicine registration

Active ingredients: ibrutinib.
ERLYAND, JANSSEN APALUTAMIDE (Janssen-Cilag Pty Ltd)

15 September 2020

Prescription medicine registration

Active ingredients: apalutamide.
TREMFYA guselkumab 100 mg solution for injection, pre-filled syringe (286020)

15 March 2018

ARTG

Australian Register of Therapeutic Goods (ARTG) information for TREMFYA guselkumab 100 mg solution for injection, pre-filled syringe.
BOSENTAN ACTELION bosentan 62.5mg (as monohydrate) tablet bottle Cancelled under Section 30(1)(c) of the Act

29 June 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
BOSENTAN ACTELION bosentan 125mg (as monohydrate) tablet bottle Cancelled under Section 30(1)(c) of the Act

29 June 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
JANSSEN DARATUMUMAB daratumumab 100 mg/5 mL concentrated solution for infusion vial Cancelled under Section 30(1)(c) of the Act

2 June 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
JANSSEN DARATUMUMAB daratumumab 400 mg/20 mL concentrated solution for infusion vial Cancelled under Section 30(1)(c) of the Act

2 June 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
TREVICTA paliperidone (as palmitate) 175 mg suspension for injection prefilled syringe Cancelled under Section 30(1)(c) of the Act

20 May 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd

Pages

First page
Previous page
…
Page 7
Page 8
Page 9
Page 10
Current page 11
Page 12
Page 13
Page 14
Page 15
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.